An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Besremi

Chemical Nameropeginterferon alfa-2b-njft
Dosage FormInjection (subcutaneous; 500 mcg/mL)
Drug ClassInterferons
SystemBlood
CompanyPharmaEssentia
Approval Year2021

Indication

  • For the treatment of adults with polycythemia vera.
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Besremi (ropeginterferon alfa-2b-njft) Prescribing Information.2021PharmaEssentia Corporation, Burlington, MA
Document TitleYearSource
Assessment report: Besremi.2021EMA